rediff.com
X   
REAL-TIME QUOTE
Enter Company or MF
e.g. Tata motors, Reliance MF, 500570
Dr. Datsons Labs Ltd.: Experts' corner
533412 DRDATSONS Group (B) BSE data
Back to Company Page
Management speaks
Dr. Kannan Vishwanath
Dr. Kannan Vishwanath
Vice Chairman
Dr. Datsons Labs Ltd.
February 21, 2012, 3:28 pm
Why should an investor buy your company's stock?

The company is in its growth phase. Post acquisition of the assets of Apex Drugs, we have a large and diversified product portfolio, large distribution network, and penetration into the emerging markets of South and Central America and Africa. We see a clear upward trend for the next five years and believe that investors can share and grow with the company in the years to come.

What events do you expect in your industry sector over the next few months? Are these hurdles or catalysts?

A lot of patents will expire by 2014 and it is a huge opportunity for generic and API companies, as it opens up new marketing avenues. We see exciting times for pharma industry.

What growth initiatives has your company planned?

The company has large manufacturing facilities and a wide range of formulations and captive API manufacturing capabilities. Formulations are being registered within India and emerging markets at a fast pace. This will ensure healthy growth for the company in the years to come.

Who is your competition? What differentiates you from them?

We are among the few mid-sized companies that are totally integrated, from APIs to formulations, and a presence in the entire value chain with our branded formulations and distribution network. This differentiates us from other mid-sized pharma companies that have a presence either in APIs or in formulations.

How do you see your company performing over the next financial year?

The company has a strong order book in place. The new facilities are shaping up well and we will start commercial production within the next three months. With added capacities, a diversified product range and large distribution network, we see strong growth in the next financial year.